Amylyx Pharmaceuticals Inc - estatísticas financeiras trimestrais (NASDAQ:AMLX) | MetaTrader

Abrir gráfico completo

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Notícias

H.C. Wainwright reitera classificação das ações da Amylyx com base no progresso do estudo

H.C. Wainwright eleva preço-alvo da Amylyx para US$ 34 com confiança no estudo

H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence

Amylyx Pharmaceuticals apresenta avanços estratégicos na TD Cowen

Ações da Amylyx caem mais de 3% com incerteza sobre estudo apesar de lucros superarem expectativas

Amylyx shares fall over 3% on trial uncertainty despite earnings beat

Stifel inicia cobertura de Amylyx com recomendação de compra

Stifel initiates Amylyx stock with buy rating on drug potential

Amylyx divulgará resultados enquanto estudo de avexitide se aproxima do fim

Amylyx set to report earnings as avexitide trial nears finish

Preço-alvo das ações da Amylyx elevado para US$ 28 de US$ 20 pela H.C. Wainwright

Amylyx stock price target raised to $28 from $20 at H.C. Wainwright